Skip to main content

About Us

ElsaLys Biotech at a glance

ELSALYS BIOTECH is a clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies that target tumors and their immune and/or vascular microenvironment.

By modulating the action of immune cells (immunomodulator antibodies) or by blocking the mechanisms that promote tumor growth (targeted antibodies), ELSALYS BIOTECH intends to offer new options to patients for whom therapy is no longer an option.

To convert these novel targets into drug candidates, the Company relies on a world-class academic network, a team and an R&D platform that encompasses targets sourcing to clinical development and the commercialization of monoclonal antibodies derived from these targets.

The company is a wholly owned subsidiary of Mediolanum Farmaceutici Spa (see the press release published on May 7, 2020).

23
Average Year Of Experience
3
Programs
15
Academic Partners

Management team

Dr Christine Guillen, PharmD

CEO and Co-founder

After holding various positions in the R&D department of LFB, Christine Guillen join

Dr Jacques Mizrahi, PhD

Vice President R&D

Jacques Mizrahi joined ElsaLys Biotech in 2014 as a consultant acting Chief Scientif

Dr David Liens, MD

Chief Medical Officer

David Liens brings more than 20 years’ experience in the field of drug development an

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.